{
    "nct_id": "NCT06607627",
    "official_title": "An Open-Label, Single-arm Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, and Efficacy of Gefurulimab in Pediatric Patients (6 to < 18 Years of Age) With Generalized Myasthenia Gravis (gMG) Who Express Acetylcholine Receptor Antibodies (AChR+)",
    "inclusion_criteria": "United States of America (USA) specific inclusion criterion:\n\n* Participant must be 12 to < 18 years of age at the time of signing the informed consent/assent.\n* All participants must be vaccinated against meningococcal infection from serogroups A, B, C, W, and Y within 3 years and at least 2 weeks prior to the first dose of study intervention administration.\n\nRest of World (ROW) specific inclusion criteria:\n\n* Participant must be 6 to < 18 years of age at the time of signing the informed consent/assent.\n* All participants must be vaccinated against meningococcal infection from serogroups A, C, W, Y (and B where available) within 3 years prior to study intervention on Day 1. If vaccination occurs < 2 weeks prior to Day 1, the participants will receive prophylactic antibiotics for at least 2 weeks after initial meningococcal vaccination for serogroups A,C,W,Y (and B, where available)\n\nGlobal inclusion criteria:\n\n* Diagnosis of MG with generalized muscle weakness meeting the clinical criteria defined by Myasthenia Gravis Foundation of America (MGFA) Class II, III or IV\n* Positive serological test for autoantibodies against AChR\nHealthy volunteers allowed\nMust have minimum age of 6 Years\nMust have maximum age of 17 Years",
    "exclusion_criteria": "* History of thymectomy, or any other thymic surgery within 12 months prior to Screening\n* Untreated thymic malignancy, carcinoma, or thymoma\n* History of Neisseria meningitidis infection\n* Pregnancy, breastfeeding, or intention to conceive during the course of the study",
    "miscellaneous_criteria": ""
}